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Abstract
Urokinase-type plasminogen activator (uPA) and plasmin have long been implicated in cancer progression. How-
ever, the precise contributions of the uPA/plasmin system to specific steps involved in cancer cell dissemination
have not been fully established. Herein, we have used a highly disseminating variant of the human PC-3 prostate
carcinoma cell line, PC-hi/diss, as a prototype of aggressive carcinomas to investigate the mechanisms whereby
pro-uPA activation and uPA-generated plasmin functionally contribute to specific stages of metastasis. The PC-hi/
diss cells secrete and activate significant amounts of pro-uPA, leading to efficient generation of plasmin in solution
and at the cell surface. In a mouse orthotopic xenograft model, treatment with the specific pro-uPA activation–
blocking antibody mAb-112 significantly inhibited local invasion and distant metastasis of the PC-hi/diss cells.
To mechanistically examine the uPA/plasmin–mediated aspects of tumor cell dissemination, the anti–pro-uPA
mAb-112 and the potent serine protease inhibitor, aprotinin, were used in parallel in a number of in vivo assays
modeling various rate-limiting steps in early metastatic spread. Our findings demonstrate that, by generating plas-
min, activated tumor-derived uPA facilitates early stages of PC-hi/diss dissemination, specifically the escape from
the primary tumor and tumor cell intravasation. Moreover, through a series of in vitro and in vivo analyses, we
suggest that PC-hi/diss–invasive escape and dissemination may be enhanced by cleavage of stromal fibronectin
by uPA-generated plasmin. Together, our findings point to inhibition of pro-uPA activation at the apex of the uPA/
plasmin cascade as a therapy-valid approach to control onset of tumor escape and ensuing metastatic spread.
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Introduction
Increased levels and activity of proteolytic enzymes have been linked
to enhanced motility, invasion, and metastasis of tumor cells [1,2].
Specifically, the serine protease urokinase-type plasminogen activator
(uPA) is often elevated in aggressive cancers, especially in prostate
cancer [3–6]. In normal tissues, uPA is tightly regulated at the level
of proenzyme activation as well as at the level of enzyme activity.
However, during cancer invasion and metastasis this tight control
of uPA system is dysregulated.
The uPA molecule is secreted as an inactive, single-chain zymo-
gen, pro-uPA, which must be proteolytically converted into an active
enzyme before it can exert its major biologic function, that is, convert
plasminogen to the active plasmin. In a reciprocal fashion, plasmin
activates the single-chain pro-uPA through hydrolysis of the Lys158-
Ile159 bond, yielding two, A and B chains, which remain covalently
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linked by a disulfide bond [7–10]. Although a secreted protease,
uPA can be tethered to the cell surface through binding of its growth
factor–like domain to the GPI-anchored cell surface receptor, uPAR
[11,12]. Both pro-uPA and activated uPA bind uPAR with similar
affinities; however, cell surface–bound uPA is significantly more potent
in the catalytic conversion of plasminogen to plasmin [13]. Plasmin
(ogen) also can be localized to the cell surface by binding to C-terminal
lysine residues of several membrane proteins, including annexin II and
Plg-RKT [14,15]. Furthermore, cell surface–bound plasmin is pro-
tected from inhibition by circulating inhibitors, thereby enhancing its
cell-associated functions [16]. The pericellular localization of both uPA
and plasmin activity is believed to facilitate cell invasion during wound
healing and tumor progression. Once activated by uPA, plasmin has a
broad substrate repertoire. Whereas the canonical function of active
plasmin is fibrin clot lysis, plasmin can also cleave several noncollagenous
components of the extracellular matrix (ECM), such as fibronectin and
laminin [17–19]. In addition, plasmin is involved in proteolytic activa-
tion of additional proteases, for example, matrix metalloprotease (MMP)
zymogens, including pro–MMP-1 and pro–MMP-3 [20,21].
Extensive evidence implicates elevated expression of uPA in malig-
nant cells and the activity of uPA/plasmin in overall tumor progression
and metastasis [7,9,22,23]. Inhibition of uPA activity by antibody and
small molecule inhibitors has been shown to diminish tumor growth,
angiogenesis, and metastasis in several model systems [6,10,24]. In ad-
dition, small interfering RNA and short hairpin RNA knockdown of
uPA expression in prostate carcinoma cells diminished their invasion
in vitro and tumor growth, angiogenesis, and dissemination to the lung
in an orthotopic mouse model [25,26], and significantly reduced bone
tumor burden and bone destruction in a bone metastasis xenograft
model [27]. Furthermore, small interfering RNA targeting of the
uPA promoter also decreased tumor growth, angiogenesis, and metas-
tasis of prostate carcinoma cells [28]. However, because of the coordi-
nate inhibitory effects on tumor growth, it was difficult to discriminate
in these studies direct inhibitory effects of uPA RNA silencing on tumor
metastasis from indirect consequences of reduced primary tumor size.
Some of the most compelling data implicating the plasminogen ac-
tivation cascade in tumor progression come from transgenic mice defi-
cient in various components of the PA system. Interestingly, most
phenotypes associated with plasminogen deficiency were not observed
in mice with an additional deficiency in fibrinogen [29]. However, in
the MMTV-PymT model of breast carcinogenesis combined with
genetic deficiency in plasminogen, spontaneous metastasis was signif-
icantly reduced without major effects on primary tumor growth [30].
Similarly, uPA deficiency resulted in greatly reduced levels of lung me-
tastasis from MMTV-PymT–induced mammary carcinomas without
affecting their growth [31]. Therefore, the single deficiency in uPA
was sufficient to reduce metastasis, affirming that uPA is the major
plasminogen activator functioning during tumor dissemination.
Despite all the evidence indicating that the uPA/plasmin system plays
a critical role in tumor metastasis, the functional contributions of pro-
uPA activation and uPA activity in the individual steps involved in the
metastatic cascade remain to be elucidated. Using a chemical proteomic
approach and function-blocking antibodies, our laboratory has previ-
ously identified activation of pro-uPA as a likely key step in the intravasa-
tion and metastatic spread of a highly disseminating variant of human
HT-1080 fibrosarcoma [32,33]. We have recently isolated a pair of
PC-3 prostate carcinoma cell variants with high and low dissemination
capacities, namely, PC-hi/diss and PC-lo/diss, and showed that these cell
variants exhibit a differential in uPA secretion and uPA activation [34].
In the present study, we sought to identify those individual events dur-
ing metastatic progression that involve uPA activation. The function-
blocking monoclonal antibody (mAb) 112 that uniquely prevents
activation of the human pro-uPA zymogen has been used to address
the contributory roles of tumor-produced uPA and uPA-generated
plasmin in specific processes involved in cancer metastasis. Our findings
from several quantitative in vitro and in vivo models demonstrate that
uPA activation and plasmin activity are critically involved in early
metastatic events, particularly in the invasive escape from the primary
tumor, which we monitored in a newly developed in vivo model of
tumor cell escape. Furthermore, toward defining the molecules medi-
ating the effects of the uPA/plasmin activation cascade, we demonstrate
that cleavage of matrix fibronectin by tumor uPA-generated plasmin
results in enhanced migration-inducing capacity of the cleaved fibro-
nectin. Together, our findings underscore a mechanism, by which ele-
vated levels of uPA expression, activation, and activity render cancer
cells with a high malignant potential due to enhanced invasive escape
from primary tumors along the plasmin-modified ECM.
Materials and Methods
Tissue Culture
Dissemination variants derived from the human PC-3 prostate
carcinoma cell line, PC-hi/diss and PC-lo/diss [34], were maintained
in Dulbecco modified Eagle medium (DMEM) supplemented with
10% fetal calf serum and 10 μg/ml gentamicin (D10).
Antibodies
The following polyclonal and mAbs were used: anti–human pro-
uPA mAb-112 [33], anti–human CD44 mAb 29-7 [34], anti–human
β1 integrin mAb P5D2 (R&D Systems, Minneapolis, MN) and α5
integrin mAb P1D6 (Chemicon, Temecula, CA), rabbit anti-CD31
(Abcam, Cambridge, United Kingdom), andmurine control IgG (Jackson
ImmunoResearch, West Grove, PA). The supernatants from hybridomas
B3/D6 (anti–avian fibronectin) and “31 or 31-2” (anti-avian laminin),
developed by D.M. Fambrough, were obtained from the Developmental
Studies Hybridoma Bank developed under the auspices of the National
Institute of Child Health andHumanDevelopment andmaintained by
the Department of Biology at the University of Iowa (Iowa City, IA).
Orthotopic Prostate Tumor Model
Orthotopic implantations of PC-hi/diss cells into the prostates of
immunodeficient mice were performed as described in Conn et al.
[34]. Briefly, 8- to 9-week-old NOD-SCID mice were purchased
from the TSRI breeding colony and maintained under the guidelines
of the TSRI Institutional Animal Care and Use Committee. Mice were
anesthetized with ketamine/xylazine and 2 × 106 of firefly luciferase–
labeled PC-hi/diss cells in 30 μl of SF-DMEMwere implanted into the
anterior prostates through an incision in the lower abdomen. After
7 days, the mice were noninvasively imaged by IVIS (Caliper Life
Sciences, Mountain View, CA) and separated into two treatment groups
containing mice with tumors of similar sizes. Mice received intraperi-
toneal injections of 150 μg of mAb-112 or control IgG in 150 μl of
phosphate-buffered saline (PBS) every 4 to 5 days. Mice were imaged
again on day 27 and sacrificed at day 28. Exposed primary tumors were
photographed, excised, and weighed, and internal organs were harvested
and frozen for Alu quantitative polymerase chain reaction (qPCR) anal-
ysis. Three separate experiments, involving a total of 14 mice treated
with control IgG and 11 mice treated with mAb-112, were performed.
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Fold changes in levels of metastasis in both treatment groups were cal-
culated compared with the mean of the IgG control group for each in-
dividual experiment, and the fold differences from independent
experiments were combined.
Chick Embryo Model for Spontaneous Metastasis
The chick embryo spontaneous metastasis model was performed
exactly as described [34]. Briefly, 2.0 × 106 PC-lo/diss or PC-hi/diss
cells in 25 μl of SF-DMEM were grafted onto the chorioallantoic
membrane (CAM) of 10-day-old embryos. For imaging experiments,
PC-lo/diss and PC-hi/diss cells were prelabeled with 5 μM Cell-
Tracker Green CMFDA (Molecular Probes, Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Developing PC-hi/diss tu-
mors were treated on days 2 and 4 with 25 μg/embryo of mAb-112 or
control IgG or 0.5 trypsin inhibitory units (TIU) of aprotinin in a 100-μl
solution containing 5%DMSO. After 5 days, tumor-bearing embryos were
injected with rhodamine-conjugated Lens culinaris agglutinin (LCA;
Vector Labs, Burlingame, CA), and tumors were excised, stretched on glass
slides, and imaged immediately using a Carl Zeiss AxioImager M1m
microscope (Carl Zeiss Microimaging GmbH, Göttingen, Germany).
Images were captured using AxioVision Re.4.6 software (Carl ZeissMicro-
imaging GmbH) and processed using Adobe Photoshop. Alternatively,
for immunohistochemical analysis and quantitative analysis of tumor
cell dissemination, embryos were sacrificed on days 6 and 7, respectively.
Tumors were weighed, excised, and fixed in Zn-formalin or frozen in
OCT, and portions of CAM distal to the primary tumor site were
harvested and frozen for Alu-qPCR analysis to determine the numbers
of spontaneously disseminated human tumor cells.
Chick Embryo Experimental Metastasis Model
Vascular arrest, extravasation, and colonization of PC-lo/diss and
PC-hi/diss cells were analyzed in an experimental metastasis model,
where 100 μl of 1 × 106 CellTracker Green–labeled cells per milliliter of
SF-DMEM was injected directly into the allantoic vein of 12-day-
old embryos. Where indicated, 0.1 TIU of aprotinin or 25 μg of
mAb-112 or control IgG was injected per embryo along with the cells.
After 10 minutes or 2 hours, groups of embryos were injected with
rhodamine-conjugated LCA, and portions of the CAM were excised
and immediately imaged without fixation using a Carl Zeiss AxioImager
microscope as described above. The levels of CAM colonization were
determined by Alu-qPCR analysis 5 days after tumor cell injections.
Quantitative Alu-PCR Analysis
Quantification of disseminated human tumor cells in chick or
murine organs was performed essentially as described [35,36]. Briefly,
genomic DNA was extracted from the tissue of interest using the
Puregene DNA purification system (Qiagen, Minneapolis, MN). Real-
time PCR was performed to amplify primate-specific Alu repeat
sequences using 10 ng of extracted genomic DNA as a template in a
Bio-RadMyIQ LightCycler (Bio-Rad, Hercules, CA). The dsDNA bind-
ing dye SYBR green (Molecular Probes, Invitrogen) was used for quan-
tification. The cycle threshold (C t) values were converted into numbers of
human cells using a standard curve generated by spiking constant num-
bers of chicken or murine cells with serially diluted human tumor cells.
Intramesodermal Microtumor Model for Tumor Escape and
Early Invasion In Vivo
PC-lo/diss and PC-hi/diss cells were labeled with 5 μM CellTracker
Green and resuspended at 2 × 106/ml. Small boluses of tumor cells
(3-5 μl) were injected directly into the mesoderm of day 9 chick
embryos developing ex ovo. Each embryo received four to six individual
injections. The developing PC-hi/diss microtumors were treated on
day 2 with 25 μg of mAb-112, mAb P1D6, or control IgG; 0.125 TIU
aprotinin; or 25 μl of 1 mM GM6001 (Calbiochem, EMD Chemicals
Inc., Gibbstown, NJ). Where indicated, the embryos were treated with
aprotinin on day 4 instead of day 2. On day 6 of microtumor develop-
ment, embryos were injected intravenously with rhodamine-LCA; por-
tions of the CAM with the microtumors were excised and immediately
imaged using a Carl Zeiss AxioImager microscope. Quantification of
tumor cell escape was performed using ImageJ software (public domain,
NIH, Bethesda, MD). The mean of the five longest invasive distances
from the microtumor-CAM border was determined for each micro-
tumor, and at least 10 individual microtumors from three to five embryos
were analyzed for each variable.
Three-dimensional Model for Tumor Cell Invasion In Vitro
PC-hi/diss cells were incorporated at a density of 1 × 106 cells/ml into
neutralized type 1 rat tail collagen used at 2.2 mg/ml (BD Biosciences,
Bedford, MA). Polymerized tumor cell–containing collagen droplets
(25 μl each) were placed atop polymerized collagen gels (1.5 mg/ml)
supplemented with EGF (20 ng/ml) and overlaid with additional
600 μl of the collagen/EGF mixture, providing a three-dimensional
matrix for cell-containing droplets after final polymerization.
Fibrin-containing three-dimensional gels were prepared by mixing
bovine fibrinogen (Sigma, Saint Louis, MO) with collagen to final con-
centrations of 3 and 1.5 mg/ml, respectively. Thrombin (Sigma) was
added at a final concentration of 10 U/ml. For fibronectin-containing
collagen gels, human fibronectin (BD Biosciences) was added to a final
concentration of 20 μg/ml. Both fibrin- and fibronectin-enriched
collagen gels were additionally supplemented with EGF to induce
directional invasion of tumor cells from collagen droplets.
After final polymerization, three-dimensional gels with cell-containing
collagen droplets were overlaid with 0.5 ml of AIM-V medium, con-
taining 0.1% chicken serum (as a source of plasminogen) and 25 μg/ml
control IgG or mAb-112. Culture medium supplemented with the
corresponding antibodies was replaced every 3 to 4 days. On day 10,
tumor cell spheroids were imaged with an Olympus CKX41 microscope
equipped with an Infinity1 camera (Olympus America Inc., Center
Valley, PA), and images were captured using Infinity Capture software.
The distances invaded by the escaping tumor cells were measured using
ImageJ software. At least six independent fields per variable were ana-
lyzed. The average length of invasion per field was multiplied by the
number of invading cells/cell clusters per field to calculate the invasion
index, and the average invasion index was determined for individual
spheroids and presented as the mean for each treatment condition.
Immunohistochemistry
Normal CAM, primary PC-hi/diss CAM tumors and mouse pros-
tate xenografts were excised and frozen in OCT for CD44, fibronectin,
and laminin staining or fixed in Zn-formalin and paraffin-embedded
for theMasson trichrome, fibrin, or CD31 staining. Frozen sections were
fixed in 2% paraformaldehyde, blocked, and probed with 1 μg/ml of
mAb-29-7 or hybridoma supernatants diluted 1:10. Standard Masson
trichrome staining was performed by the Histology Core Facility at the
Scripps Research Institute on paraffin-embedded tumor sections. For
fibrin(ogen) staining, CAM tumor sections were probed with rabbit
antifibrin (DAKO, Carpentia, CA) diluted 1:300, which cross-reacts
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with avian fibrin. Mouse xenograft tumor sections were probed with
5 μg/ml rabbit anti-CD31.
After incubations with primary antibodies, sections were probed
with corresponding biotinylated secondary antibodies (Vector Labs).
All stained tissue sections were finally incubated with avidin-D horse-
radish peroxidase (HRP) conjugate (Vector Labs) for 30 minutes,
developed with a diaminobenzidine chromogenic substrate, and coun-
terstained with Mayer hematoxylin. Images were captured using an
Olympus BX60 microscope equipped with a digital DVC videocamera
(DVC, Austin, TX) and processed with Adobe Photoshop 6.0 software.
Western Blot Analysis
Conditioned medium (CM) from equal cell numbers (as deter-
mined by cell counting) or cell lysates containing equal amounts of
proteins (as determined using the BCA protein assay; Pierce; Thermo
Scientific, Rockford, IL) were boiled in SDS buffer with or without
100 mM dithiothreitol. Samples were separated on 4% to 20% Tris-
glycine SDS-PAGE gels (Invitrogen) and transferred to Immobilon-P
polyvinylidene fluoride membranes (Millipore, Billerica, MA). Mem-
branes were blocked in PBS–Tween 20 containing 5% milk and
probed with the indicated primary antibodies. Membranes were incu-
bated with secondary anti-rabbit (Pierce) or antimouse (Bio-Rad) HRP-
conjugated antibodies, and immunoreactive bands were visualized using
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
uPA Activation
PC-lo/diss and PC-hi/diss cells were seeded at equal densities and
incubated overnight in D10. Cell monolayers were washed briefly
with serum-free DMEM (SF-DMEM), which seems to preserve traces
of serum plasminogen associated with the cell surfaces. Cell monolayers
were then overlaid with SF-DMEM for additional incubation for 24 or
48 hours. Where indicated, the cells were incubated in the presence of
0.1% chicken serum, as a source of additional plasminogen, and 25 μg/ml
control IgG or mAb-112, 0.1 TIU/ml aprotinin, or 20 μg/ml α2-
antiplasmin (Calbiochem). The activation status of uPA in the CM
was analyzed by Western blot analysis under reducing conditions.
Plasmin Generation Assays and uPA Activity Measurements
For plasmin generation, CM was incubated at 37°C with 10 μg/ml
human plasminogen (123 nM) and 0.5 mM S-2251 chromogenic plas-
min substrate (Chromogenix Instrumentation Laboratory, Lexington,
MA). Where indicated, the CM was preincubated with the chemical
uPA inhibitor amiloride (50 μM), 167 nM (25 μg/ml) of mAb-112, or
4 μM aprotinin (0.1 TIU/ml) for 25 minutes at room temperature before
the addition of plasminogen and S-2251. The OD was read at 405 nm
every 1minute or 2minutes using a spectrophotometer. Background read-
ings of CM and S-2251 in the absence of plasminogen were subtracted.
To measure uPA-generated plasmin activity at the cell surface, cell
monolayers were extensively washed and then incubated for 15 minutes
with 8 μg/ml of plasminogen (100 nM). The collected supernatants
were incubated with 0.5 mM of S-2251 substrate to determine plasmin
activity. Alternatively, after an extensive wash, cell monolayers were
treated with pH 3.5 glycine-HCl containing isotonic NaCl for 10 min-
utes at room temperature to strip cell surface–bound uPA. The solution
was neutralized with 50 mM HEPES, and the plasmin-generating
capacity of the stripped uPA was analyzed as described previously using
S-2251 and human plasminogen.
Fibronectin Cleavage and Tumor Cell Migration in Transwells
Human fibronectin (200 μg/ml) was incubated overnight at 37°C with
human plasmin (Sigma) at a 10:1molar substrate/enzyme ratio in the pres-
ence or absence of 1 TIU/ml aprotinin. Alternatively, fibronectin was
incubated overnight at 37°C in PC-hi/diss CM alone or in the presence
of 12 μg/ml human plasminogen with or without 1 TIU/ml aprotinin.
Samples containing 5 μg of fibronectin were separated by SDS-PAGE
on 4% to 20% Tris-glycine gels under nonreducing conditions. The gels
were stained with Coomassie blue dye to visualize the major protein bands.
For fibronectin-induced migration, the undersides of Transwell
membranes with 8-μm pores (Corning Life Sciences, Pittston, PA)
were coated with 10 μg/ml fibronectin for 1 hour at 37°C. To par-
tially cleave the coated fibronectin, the Transwells were incubated over-
night at 37°C with plasmin (5 μM). PC-hi/diss cells were placed at 1 ×
105 per insert in SF-AIM-V medium and allowed to migrate for 18 to
24 hours. Cells in the outer chambers were collected and counted.
Experiments were performed in duplicate, with two wells per variable
in each experiment.
Data Analysis and Statistics
Data processing and statistical analysis were performed using
GraphPad Prism (GraphPad Software, Inc, San Diego, CA). Data were
considered significantly different for P < .05 in Student’s t test or
Mann-Whitney U test.
Results
High Levels of Pro-uPA Activation and uPA-Generated
Plasmin Activity Correspond to High Levels of Tumor
Cell Dissemination
To assess whether the respectively high- and low-dissemination
capacities of the PC-hi/diss and PC-lo/diss cell variants correlated
with their ability to generate active plasmin, a coupled plasmin activ-
ity assay was performed on samples of CM. In this assay, exogenous
plasminogen must be activated to cleave the plasmin-specific substrate,
S-2251. Substantially enhanced plasmin generation was observed in
PC-hi/diss CM compared with PC-lo/diss CM (Figure 1A, graphs),
consistent with higher levels of total uPA protein, represented by
the single-chain pro-uPA and also the two-chain active uPA, which
accumulated in the PC-hi/diss CM during 24 hours of incubation,
as judged by Western blot analysis (Figure 1A, right).
Because cell surface protease localization facilitates the efficient
proteolysis of ECM and transmembrane molecules, we also examined
the ability of PC-hi/diss and PC-lo/diss cells to generate active plasmin
at the cell surface. Purified plasminogen was incubated for 15 minutes
directly with cell monolayers of increasing densities of PC-lo/diss or
PC-hi/diss cells, and the extent of plasmin generation was determined
by measuring S-2251 cleavage in the resulting supernatants (Figure 1B).
In this approach, most of the generated plasmin results from the activity
of cell surface uPA because the short incubation time does not yield sig-
nificant levels of secreted uPA. In a second confirmatory approach, cell
surface–bound uPA was stripped from PC-lo/diss and PC-hi/diss culture
monolayers, and the ability of the released uPA to activate plasminogen
was assessed using the chromogenic assay (Figure 1C). Both methods
indicated substantially greater cell surface plasmin-generating capacity
associated with the PC-hi/diss cells compared with the PC-lo/diss cells.
It is important to note that the differential in cell surface uPA activity
between the PC-3 variants was not attributable to differences in the
expression of uPA receptor uPAR because uPAR levels were similar
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between the low- and high-disseminating counterparts (Figure W1).
Thus, the PC-3 variants not only manifest differential secreted and sur-
face levels of pro-uPA and active uPA protein but also exhibit a substan-
tial differential in functional plasmin-generating capacities, both at the
cell surface and in the solution.
The detection of active uPA in the CM and on the surface of PC-hi/
diss cells indicated the presence of a pro-uPA activator in the model
systems. Although the transmembrane serine proteases matriptase
and hepsin have been demonstrated to activate uPA [37–39], the gene
expression levels of both these proteases in the PC-hi/diss cells were
extremely low or undetectable (data not shown). However, plasmin gen-
erated from plasminogen is known to be a major feedback activator of
pro-uPA [8], and both plasma and serum are the major natural sources
of plasminogen in vivo and in vitro. When the PC-hi/diss cells were
supplemented with 0.1% chicken serum as a source of plasminogen/
plasmin, nearly all secreted pro-uPA (>95%) was activated to the two-
chain form, suggesting that serum plasmin could be a major pro-uPA ac-
tivator (Figure 1D, lane 1). To confirm this notion, the potent plasmin
inhibitor, aprotinin, and the natural plasmin inhibitor, α2-antiplasmin,
were added to the PC-hi/diss cell cultures. Both inhibitors completely
abrogated the conversion of PC-hi/diss pro-uPA to the two-chain active
uPA, strongly implicating serum plasmin as a major feedback activa-
tor of pro-uPA in this system (Figure 1D, lanes 2 and 4). In addition,
generation of the two-chain uPA was almost completely inhibited by
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anti-uPAmAb-112 (Figure 1D, lane 3), previously shown to specifically
block activation of pro-uPA [33]. Therefore, plasmin-mediated activa-
tion of pro-uPA can be effectively prevented in vitro by specifically
blocking either plasmin activity or pro-uPA activation.
Furthermore, when mAb-112 was incorporated into the PC-hi/diss
CM, the rate of S-2251 cleavage in a plasmin generation assay was sig-
nificantly reduced, further implicating pro-uPA activation in a feedback
uPA/plasmin(ogen) activation cascade (Figure 1E). The uPA activity-
blocking inhibitor, amiloride, also substantially slowed the plasmin-
generating ability of PC-hi/diss CM. As expected, the direct targeting of
plasmin with aprotinin completely inhibited the uPA-generated plasmin
activity (Figure 1E). These in vitro findings suggested that specific in-
hibition of pro-uPA activation with mAb-112 might produce substan-
tial inhibitory effects on plasmin generation in metastasis assays in vivo.
Inhibition of Pro-uPA Activation Reduces Invasion and
Spontaneous Dissemination of PC-hi/diss Cells in an
Orthotopic Xenograft Model
To determine the functional contribution of uPA activation to
carcinoma cell dissemination, we used mAb-112 in an orthotopic
xenograft model, in which PC-hi/diss cells were implanted into the
prostates of NOD/SCID mice. Seven days after cell implantations,
tumor-bearing mice were imaged and separated into two groups
for treatment with mAb-112 or control mouse IgG, delivered intra-
peritoneally every 4 days (Figure 2A, top). On day 28, large primary
tumors that had developed within the prostate region were observed
in both groups of mice (Figure 2A, bottom). The presence of large
prostate primary xenografts of similar size was visually confirmed
in both treatment groups (Figure 2B, left). The weights of the pri-
mary PC-hi/diss prostate tumors indicated no significant differential
in tumor growth between the control IgG- and mAb-112–treated
mice (Figure 2D).
The axial and subiliac lymph nodes (LNs) were enlarged in both treat-
ment groups, although node enlargement was more pronounced in the
control mice (Figure 2B, middle). A similar trend was noted for the rate
of mesenterium colonization, observed in 45% of control mice versus
25% of mAb-112–treated animals. Furthermore, control animals de-
veloped much larger tumor colonies on the mesenterium compared with
mAb-112–treated mice (Figure 2B, right), indicating inhibitory effects
of mAb-112 on intraperitoneal dissemination of PC-hi/diss tumor cells.
To analyze the effects of mAb-112 treatment on tumor development
and local invasion, adjacent sections of primary prostate tumors were
immunostained with human-specific anti-CD44 antibody to highlight
the human tumor cells and with anti-CD31 to highlight the murine
blood vessels (Figure 2C). Whereas the tumors from control IgG-treated
mice manifested jagged invasive fronts and nests of escaped tumor cells
(Figure 2C , two left panels in IgG control ), the tumors from mAb-112–
treated mice appeared confined and exhibited smooth tumor bor-
ders (Figure 2C , top panels in mAb-112 group). Furthermore, whereas
PC-hi/diss primary tumor cells from the control mice were observed in
close association with CD31-positive blood vessels and detected intra-
vascularly (Figure 2C , right panels in IgG control ), the tumor cells from
mAb-112–treatedmice did not seem to engage in such interactions, even
in areas with relatively high vessel density (Figure 2C , right panels
in mAb-112 group). Thus, the immunohistochemical analysis of the
orthotopic prostate xenografts indicated that treatment with mAb-112
reduced local invasion and tumor cell–blood vessel interactions.
Levels of tumor cell dissemination to internal organs were quanti-
fied by Alu-qPCR, which indicated that, compared with the control,
the mAb-112 treatment significantly diminished PC-hi/diss metastasis
to the lungs (by 58%, P < .05), liver (by 67%, P < .05), and brain (by
87%, P < .01). Levels of metastasis in the colonized LNs were also de-
creased by 50% in the inguinal LNs and by 54% in the axillary LNs;
however, although a clear trend was observed, the diminishment was not
statistically significant (Figure 2D). Overall, the findings from the ortho-
topic implantation model indicated that blocking activation of tumor
cell–produced pro-uPA can significantly inhibit levels of spontaneous
dissemination by highly malignant prostate carcinoma cells.
Figure 1. High levels of plasmin-generating ability of PC-hi/diss cells correlate with high levels of secreted and cell surface uPA and its
activation status. (A) Plasmin-generating activity of uPA secreted by PC-hi/diss and PC-lo/diss cells. CM from PC-hi/diss and PC-lo/diss
cultures was collected after 5 (left graph) and 18 hours (right graph) of incubation. Plasminogen was added to the CM to a final con-
centration of 123 nM, and cleavage of chromogenic plasmin substrate, S-2251, was analyzed at indicated time points by measuring
optical density at 405 nm. Far right: uPA detected by Western blot analysis under reducing conditions in 24 hr CM from PC-lo/diss and
PC-hi/diss cells (lanes 1 and 2, respectively). Positions of the 50-kDa proenzyme, 33-kDa B-chain, and 19-kDa A-chain are indicated
by arrows. (B) Plasmin-generating activity of cell surface–associated uPA. PC-hi/diss and PC-lo/diss cells were seeded at increasing
densities, washed and incubated for 15 minutes in SF-DMEM supplemented with 100 nM plasminogen, followed by direct measure-
ment of plasmin activity with the chromogenic substrate, S-2251. (C) Plasmin-generating activity of receptor-bound uPA. Cell surface
uPA was stripped from the PC-lo/diss or PC-hi/diss cell monolayers with a 10-minute isotonic acid wash. After neutralization, plasmin-
generating ability of stripped uPA was determined in a coupled S-2251 cleavage assay in the presence of 123 nM plasminogen. (D) Ac-
tivation status of uPA produced by PC-hi/diss cells and its inhibition by serine protease inhibitors and activation-blocking mAb-112. PC-hi/
diss cells were incubated with control IgG, anti-uPAmAb-112, or indicated inhibitors, aprotinin and α2-antiplasmin (a2-AP). Chicken serum
was added at 0.1% to the cultured cells as a source of plasminogen to initiate a plasmin-generating cascade. After incubating for
48 hours, samples of CM were analyzed by Western blot for uPA. Lane 1, pro-uPA is almost completely converted to a two-chain enzyme
in the IgG control; lanes 2 and 4, aprotinin and a2-AP completely abrogated activation of pro-uPA; lane 3, mAb-112 significantly inhibited
conversion of single-chain pro-uPA zymogen into the two-chain uPA enzyme. Positions of the molecular weight markers (kDa) are
indicated on the right. (E) Inhibition of uPA-generated plasmin activity by mAb-112. CM, containing a mixture of pro-uPA and active
uPA produced by PC-hi/diss cells cultured in SF-DMEM for 24 hours, was incubated with control IgG, mAb-112, the chemical inhibitor
of uPA activity amiloride or the plasmin inhibitor aprotinin. Plasminogen and the chromogenic S-2251 substrate were added to the CM
to final concentrations of 100 and 0.5 mM, respectively, and the activity of the generated plasmin was determined by rate of S-2251
cleavage. Aprotinin completely prevented S-2251 cleavage, and there was no S-2251 cleavage in the presence of plasminogen alone
(No CM).
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Preventing uPA Activation Reduces Capacity of Tumor Cells
to Complete Early Metastatic Events in the Chick Embryo
CAM Model
The inhibitory effects of mAb-112 on PC-hi/diss on overall sponta-
neous dissemination (Figure 2) could be caused by blocking pro-uPA
activation either during early metastatic events (i.e., those leading to
intravasation) or during later events (such as survival in circulation,
arrest, and colonization). To address the functional contribution of
uPA activation to various steps in the metastatic process, we turned to
chick embryo models, which allow for efficient and quantitative analysis
of tumor cell intravasation as well as for direct imaging of tumor cells
during specific stages of the metastatic process.
Because mAb-112 reduced local invasion in the prostate xenograft
model, we first analyzed whether a similar effect would be elicited in pri-
mary CAM tumors. To this end, PC-hi/diss cells were labeled with Cell-
Tracker dye and grafted atop the CAMs of day 10 chick embryos. The
developing tumors were left untreated or treated topically withmAb-112,
to inhibit pro-uPA activation, or aprotinin, to inhibit plasmin activity. In
parallel, PC-lo/diss cells, expressing low levels of pro-uPA, were also pre-
labeled with CellTracker and then grafted onto the CAM. After 5 days,
the embryos were injected with rhodamine-conjugated LCA to highlight
the avian vasculature, and primary tumors were immediately analyzed
using a fluorescence microscope. Whereas primary tumors developed
from PC-lo/diss cells displayed smooth borders and almost complete
absence of invasion, PC-hi/diss tumors manifested jagged borders and
extensive collective invasion of tumor cells into the surrounding CAM
tissue (Figure 3A). However, the treatment of developing PC-hi/diss tu-
mors with mAb-112 or aprotinin substantially reduced the extent of
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primary tumor invasion (Figure 3A), implicating pro-uPA activation and
active uPA-generated plasmin, respectively, in the invasive processes at
the primary tumor site. Quantification of actual numbers of disseminated
tumor cells in the distal CAM by Alu-qPCR confirmed that both mAb-
112 and aprotinin dramatically reduced spontaneous dissemination from
PC-hi/diss tumors almost to the levels of the nondisseminating PC-lo/
diss variant (Figure 3B). These profound inhibitory effects of blocking
the uPA/plasmin system on local invasion and spontaneous metastasis
of PC-hi/diss cells indicated that pro-uPA activation and uPA-generated
plasmin activity can play critical roles during early metastatic events.
To address potential effects of mAb-112 and aprotinin on later
metastatic events, especially vascular arrest and initial extravasation,
PC-hi/diss cells were labeled with CellTracker and directly injected
into the CAM vasculature in the presence or absence of aprotinin
or mAb-112, thereby bypassing the intravasation step. In parallel,
CellTracker Green–prelabeled PC-lo/diss cells were also inoculated into
the chick embryo vasculature. After 10 minutes, both PC-lo/diss and
PC-hi/diss cells seemed to be in circulation because most of the injected
tumor cells in the CAM were observed intravascularly (Figure 4A, top).
However, by 2 hours, the PC-lo/diss and PC-hi/diss cells had already
arrested in the terminal capillaries and had begun to extravasate from
the capillary plexus. PC-hi/diss cells seemed similarly capable of efficient
arrest and extravasation at 2 hours in the embryos injected with control
IgG, mAb-112, or aprotinin (Figure 4A, bottom), suggesting that tumor
cell arrest and exit from the vasculature can proceed in the absence of
uPA activation and plasmin activity. Levels of CAM colonization by
PC-lo/diss and PC-hi/diss cells were quantified 5 days after tumor cell
injection by Alu-qPCR. In contrast to the profound differential in spon-
taneous dissemination from primary PC-lo/diss and PC-hi/diss tumors,
the levels of colonization were similar between PC-lo/diss and PC-hi/diss
variants (Figure 4B). The levels of CAM colonization by PC-hi/diss
cells were not significantly reduced by mAb-112 (23% of control, P =
.142) but were diminished 44% by aprotinin (Figure 4B), in sharp
contrast to the dramatic inhibition of PC-hi/diss spontaneous metastasis
by both mAb-112 and aprotinin (Figure 3B). These results indicate that,
in our model systems, activated tumor cell–derived uPA may facilitate
mainly early metastatic events such as primary tumor escape and invasive
entry into the vasculature; however, the uPA/plasmin cascade may also
have some effect on later metastatic events.
Functional Role of Pro-uPA Activation and uPA-Generated
Plasmin Activity in Cell Escape from the Primary Tumor
To directly manipulate and quantify the extent of tumor invasion
and tumor cell escape in vivo, we developed a model in which micro-
tumors are established within the mesoderm layer of the CAM
(Figure 5A). Within 5 to 6 days after microinjections, tumor cells
can be observed escaping from well-formed microtumors and invad-
ing the surrounding stroma, making this model useful for testing the
invasion-blocking activity of antiproteolytic agents.
Small boluses of CellTracker Green–labeled PC-lo/diss and PC-hi/
diss cells were injected directly into the CAM mesoderm of day 9
embryos developing ex ovo. The developing PC-hi/diss microtumors
were additionally treated with mAb-112, aprotinin or vehicle control.
After six additional days, the embryos were injected with rhodamine-
conjugated LCA, and the intramesodermal microtumors were imaged
without fixation. In comparison with PC-lo/hiss, PC-hi/diss cells exhib-
ited higher levels of tumor cell escape from intramesodermal micro-
tumors (Figure 5, B and C). However, when PC-hi/diss microtumors
were treated with mAb-112 or aprotinin on day 2 after cell injection,
a significant and substantial reduction in invasion was observed compared
to the control (Figure 5, C-E), which was confirmed by quantitative anal-
ysis (Figure 5H ). Interestingly, a broad-spectrum MMP inhibitor,
GM6001, did not have a significant effect on PC-hi/diss invasion (Figure 5,
G andH), suggesting that MMP activity does not play a dominant role in
the early escape of PC-hi/diss cells in this in vivo model system. Impor-
tantly, no significant inhibition of invasion was observed if PC-hi/diss mi-
crotumors were treated with aprotinin at a late time point, that is, on day 4
instead of day 2 (Figure 5, F and H), indicating that uPA-generated plas-
min is functionally involved during initial tumor cell escape and invasion.
Figure 2. Inhibition of spontaneous metastasis of PC-hi/diss carcinoma cells in a murine orthotopic model of prostate cancer by treat-
ment with mAb-112. (A) PC-hi/diss cells, tagged with firefly luciferase, were implanted into anterior prostates of NOD-SCID mice. After
7 days, mice were injected intraperitoneally with luciferin, imaged by IVIS and allocated evenly into two treatment groups. Levels of
bioluminescence in the prostate region were similar at this time, indicating comparable initial tumor sizes (top panels). After 28 days,
tumor-bearing mice treated with control IgG or mAb-112 were imaged again (bottom panels). One of the control mice presented exten-
sive tumor cell ascites (far left bottom panel). However, levels of bioluminescence in the prostate area were similar in the mice from both
treatment groups. (B) Gross morphology of primary prostate tumors (T, outlined with dotted line), enlarged inguinal LNs (circled with
dotted line), and macroscopic tumor colonies in the mesenterium (yellow arrows). (C) Immunohistochemical staining of consecutive
sections of prostate xenografts from mice treated with control IgG or mAb-112 (boxed panels on the left and right, respectively). To
discriminate human tumor cells from the mouse stroma, sections were stained (brown) with human-specific anti-CD44 (top panels).
Vasculature was highlighted (brown) by staining with anti-CD31 (bottom panels). In the control IgG group, gray arrowheads point to
a nest of CD44-positive tumor cells (top), whereas gray arrows in a consecutive section point to the blood vessels associated with tumor
nests (bottom). CD44-positive tumor cells, which seem to localize intravascularly, are indicated by black arrowheads (right top panel);
the intravascular localization of these cells is confirmed by CD31 staining of capillaries indicated by solid black arrows (right bottom
panel). In the mAb-112–treated group, black arrows (right bottom panel) point to blood vessels localized close to the tumor border, but
not interacting with or encompassing the nearby tumor cells (brown staining, right top panel). Numbers above scale bars indicate length
in micrometers. (D) Primary tumors were excised and weighed, indicating no difference in primary tumor size. Levels of metastasis to
the liver, lungs, brain, and LNs (inguinal and axillary) were quantified by Alu-qPCR. Percent inhibition was calculated from pooled data for
mAb-112–treated mice (n = 11) in comparison to IgG control mice (n = 14) in three individual experiments. Levels of metastasis in LNs
were determined for the nodes positive for human cells; 9 of 14 inguinal and 11 of 14 axillary nodes were positive in the control group,
whereas 7 of 11 nodes of both types were positive in the mAb-112 group. Bars represent means ± SEM. *P < .05, Mann-Whitney test.
**P < .05, two-tailed Student’s t test.
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Fibronectin as a Putative Substrate Mediating the
Metastasis-Promoting Effects of uPA and
uPA-Generated Plasmin
Although uPA itself has a very limited substrate specificity, uPA-
generated plasmin has a broad substrate repertoire that includes
various noncollagenous matrix components. To determine whether
canonical plasmin substrates might be deposited within the primary
tumors or at the tumor borders, PC-hi/diss CAM tumors were im-
munohistochemically stained for the plasmin substrates fibronectin,
laminin, and fibrin (Figures 6 and W2). The tumor distribution of
collagen was also analyzed because plasmin is known to activate po-
tent collagenases, such as MMP-1 and MMP-13, capable of efficient
collagen cleavage [40,41]. A group of PC-hi/diss tumors treated with
aprotinin were included in parallel staining to determine whether the
diminishment of tumor invasion and metastasis caused by inhibiting
the uPA/plasmin cascade would be accompanied by changes in the
composition of the tumor tissue matrix.
PC-hi/diss primary tumors were stained with anti-human CD44
mAb to discriminate tumor cells within the CAM tissue (Figure 6,
top). In consecutive sections, avian fibronectin was detected at high
levels both at the tumor border and within tumors and seemed to ac-
cumulate especially in primary tumors treated with aprotinin (Figure 6,
middle). Laminin, however, was not observed around or within primary
tumors and was localized mostly to medium-to-large vessels in both
treated and control tumors (Figure W2, top). Although fibrin is a crit-
ical physiological substrate of plasmin, only a few sparse intravascular
fibrin deposits were detected in control and aprotinin-treated tumors
(Figure W2, bottom). Extensive deposition of collagen compared to
normal CAM was observed near the primary tumor border, but the
pattern of collagen staining was not significantly affected by aprotinin
treatment (Figure 5, bottom).
The immunohistochemical and histologic analyses of ECM com-
ponents indicated that fibronectin and collagen were major compo-
nents of the PC-hi/diss tumor stroma. To validate the involvement
of active uPA in the invasion of PC-hi/diss cells into this complex
tissue matrix, we used an in vitro model of three-dimensional tumor
cell escape from spheroids into collagen gels enriched in specific ECM
components and additionally supplemented with EGF to induce cell
migration (Figure 7). If the matrix contained collagen alone, the presence
of mAb-112 did not affect escape of PC-hi/diss cells from spheroids
(Figure 7, A and B). However, when the canonical plasmin substrate,
fibrin, was incorporated into the surrounding collagen matrix, cell es-
cape was significantly inhibited by mAb-112 to 40% of control levels
(Figure 7B). Furthermore, when fibronectin was added to the collagen
scaffold, mAb-112 also reduced the PC-hi/diss tumor cell escape by
50% (Figure 7B). Thus, the in vitro escape of PC-hi/diss cells into
both types of complex matrices requires uPA activation. These data
are consistent with our in vivo results demonstrating that PC-hi/diss
cells can escape from both primary CAM tumors and intramesodermal
microtumors and that this escape into the more natural collagen/
fibronectin–rich tumor stroma was sensitive to mAb-112.
Limited Cleavage of Fibronectin by uPA-Generated Plasmin
Enhances PC-hi/diss Migration In Vitro and May Contribute
to α5β1 Integrin-Mediated Tumor Escape In Vivo
Cleavage of fibronectin can constitute one of the mechanisms whereby
uPA-generated plasmin may contribute to increased cancer cell inva-
sion and dissemination. Supporting this idea, Western blot analysis
revealed a prominent increase in the levels of high-molecular weight
fibronectin in the aprotinin-treated CAM tumors compared with control
tumors (FigureW3), confirming the apparent accumulation of immuno-
detectable fibronectin in CAM tumors treated with aprotinin (Figure 6).
We therefore further analyzed whether PC-hi/diss–mediated plasmin
Figure 3. Tumor invasion in spontaneous metastasis is inhibited
by interfering with uPA activation or plasmin activity. (A) Levels
of local invasion in primary tumors. PC-lo/diss and PC-hi/diss cells
were labeled with CellTracker Green and grafted onto the CAM.
Developing PC-hi/diss tumors were additionally treated with con-
trol IgG, pro-uPA activation-blocking mAb-112, or the plasmin in-
hibitor aprotinin on days 2 and 4. On day 5, embryos were
injected with rhodamine-conjugated lectin to highlight the CAM
vasculature (red), and primary tumors (green) were immediately
imaged without prior fixation. Tumor-CAM borders are indicated
with white lines, illustrating significant CAM invasion only in the
PC-hi/diss control tumors. Images were acquired at an original
magnification of ×100. Scale bar, 50 μm. (B) Levels of spontane-
ous dissemination to the distal CAM were quantified after 7 days
of tumor development by Alu-qPCR analysis. Data are presented
as number of human cells per 106 chicken cells. A total of 8 to 21
embryos per variable were used in two independent experiments.
Lines in scatter plots represent means. **P < .01 and *P < .05,
two-tailed Student’s t test.
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generation would promote fibronectin cleavage and whether plasmin-
cleaved fibronectin would induce PC-hi/diss cell migration.
First, fibronectin was incubated with PC-hi/diss CM in the pres-
ence or absence of plasminogen and aprotinin (Figure 8A). Although
incubation of fibronectin in buffer (Figure 8A, lane 2) or with PC-hi/
diss CM alone (data not shown) did not induce its cleavage, the addi-
tion of plasminogen to PC-hi/diss CM resulted in substantial cleavage
of fibronectin into fragments of various sizes (Figure 8A, lane 3). This
fragmentation of fibronectin was completely abrogated by aprotinin
(Figure 8A, lane 4). Fibronectin was not cleaved when incubated with
plasminogen in the absence of any source of active uPA (Figure 8,
lane 5). Thus, these results indicate that the activation of plasmin by
PC-hi/diss–derived plasminogen activators can drive the generation of
functionally important fibronectin fragments.
We addressed whether plasmin-induced fibronectin fragmentation can
functionally contribute to increased PC-hi/diss cell motility (Figure 8B).
To this end, Transwells were coated with fibronectin and either left intact
or incubated with plasmin in the presence or absence of aprotinin. Analy-
sis of protein-stained gels confirmed partial, aprotinin-sensitive cleavage
of fibronectin by plasmin (Figure 8B, bottom). The haptotactic migra-
tion of PC-hi/diss cells toward nontreated or plasmin-treated fibronectin
indicated that limited cleavage of fibronectin by plasmin significantly
enhanced PC-hi/diss migration by more than 2.5-fold and that this
enhancement was sensitive to aprotinin (Figure 8B, bar graph). This
cell migration response did not seem to be due to a differential ability
of PC-hi/diss cells to adhere to intact versus plasmin-treated fibronectin
because cells adhered to both intact and cleaved fibronectin with similar
efficiency (Figure W4A). The expression and functionality of the major
Figure 4. Initial stages of experimental metastasis is independent of uPA/plasmin(ogen) activation system. (A) Arrest and initial extrav-
asation of tumor cells is independent of mAb-112 and aprotinin. Day 12 embryos were injected with rhodamine-conjugated lectin. After
15 to 20 minutes, single-cell suspensions of CellTracker Green–labeled PC-lo/diss cells or PC-hi/diss cells, mixed with control IgG, mAb-112,
or aprotinin, were directly injected into the allantoic vein. Ten minutes and 2 hours later, portions of the CAM were immediately imaged by
immunofluorescence microscopy. Green fluorescent tumor cells were visualized still within the CAM vasculature at 10 minutes (top) or as
initiating extravasation from the ectoderm capillary plexus at 2 hours after injection (bottom). No major morphologic differences were ob-
served between PC-lo/diss and PC-hi/diss cells or between the control IgG- and mAb-112– or aprotinin-treated PC-hi/diss cells. Images were
acquired at an original magnification of ×100. Scale bar, 50 μm. (B) Levels of CAM colonization were determined by Alu-qPCR 5 days after
intravenous inoculation of PC-lo/diss or PC-hi/diss cells mixedwith indicated additives. Pooled data are presented from two (PC-lo/diss) to six
(PC-hi/diss, aprotinin) individual experiments, using a total of 14 to 76 embryos per variant. Levels of colonization in individual embryos were
determined as percent of PC-hi/diss control. Data are presented as mean ± SEM. ***P < .001.
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fibronectin receptor, α5β1 integrin, were confirmed in PC-hi/diss cells
by FACS analysis (Figure W4B), and function-blocking mAbs against
α5 and β1 integrin subunits completely abrogated the binding of PC-hi/
diss cells to intact as well as to plasmin-treated fibronectin (Figure W4A).
To validate the functional importance of fibronectin to invasion and
escape of PC-hi/diss cells in vivo, intramesodermal microtumor assays
were performed in the presence of a function-blocking mAb preventing
the interaction between α5β1 integrin and its ligand, fibronectin. The
P1D6 mAb, which specifically targets the α5 integrin subunit, was used
due to the known ability of the β1 subunit to engage in interactions
with multiple α subunits and the wide substrate repertoire of β1 integrin
complexes. Thus, PC-hi/diss microtumors were treated with anti-α5
Figure 5. Activation of uPA facilitates early escape and invasion of PC-hi/diss tumor cells in vivo. (A) Left, Hematoxylin and eosin–stained
section of the CAM depicting the endoderm, ectoderm capillary plexus, and mesoderm. Middle, Schematic and photographic depictions
of tumor cell injection into the CAM mesoderm. Right, Intramesodermal microtumor developed 5 days after cell injection. (B-G) CellTracker
Green–labeled PC-lo/diss and PC-hi/diss cells were intramesodermally injected into day 9 embryos. Developing PC-hi/diss microtumors were
topically treated on day 2 (C-E) or day 4 (F) with control IgG (C),mAb-112 (D), aprotinin (E and F), or GM6001 (G). At day 6 after cell inoculations,
microtumor-bearing embryos were injected with rhodamine-conjugated lectin, and portions of the CAM containing microtumors were
excised and immediately imaged. Images were digitally acquired at an original magnification of ×100. Panels B to G depict representative
microtumors from control and each of treatment groups. Microtumor borders and invasion distances of green fluorescent tumor cells are
indicated by white lines. Scale bar, 50 μm. (H) Quantification of microtumor invasion was performed in digitally captured images by averag-
ing the five longest distances of invasion for eachmicrotumor. Data are presented as percent PC-hi/diss invasion in IgG control (100%), calcu-
lated for 10 to 16 individual microtumors per variable and are means ± SEM. **P < .001 and ***P < .0001, two-tailed Student’s t test.
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mAb on day 2 of microtumor development, and the extent of cell
escape from the microtumors was analyzed and quantified by immuno-
fluorescence microscopy at day 6 (Figure 8C). Preventing α5β1 integrin–
mediated cell interactions with fibronectin significantly reduced tumor
cell invasion into the stroma surrounding the microtumors (Figure 8C ,
bar graph), thus validating the importance of an interaction between the
escaping tumor cells with fibronectin. In conjunction with the above-
described stimulation of PC-hi/diss migration by plasmin-treated fibro-
nectin and the sensitivity of PC-hi/diss invasion to the plasmin inhibitor
aprotinin, these results indicate that fibronectin may be a critical plasmin
substrate involved in promoting the in vivo invasion, escape, and dis-
semination of PC-hi/diss cells.
Discussion
Herein, we have demonstrated the efficacy of preventing uPA activa-
tion as a strategy to inhibit intravasation and dissemination of human
cancer cells by targeting the proteolysis-driven initial escape of cancer
cells from the primary tumor. In a mouse prostate orthotopic metas-
tasis model, the treatment of PC-hi/diss tumor-bearing mice with
pro-uPA activation-blocking mAb-112 significantly inhibited local
invasion and metastatic dissemination to secondary organs, including
the brain, liver, and lungs. Furthermore, by using mAb-112 in a series
of chick embryo models, we determined that pro-uPA activation trig-
gers the onset of invasive escape of PC-hi/diss cells from primary
tumors and that the specific targeting of pro-uPA activation was highly
effective in reducing levels of spontaneous metastasis.
The serine protease inhibitor aprotinin also substantially inhibited
escape, invasion, and dissemination in the chick embryo models.
Aprotinin is a potent inhibitor of plasmin, a major feedback activator
of pro-uPA as well as the key catalytic product generated by uPA-
mediated activation of plasminogen [8]. Therefore, inhibition of PC-
hi/diss spontaneous dissemination in the CAM model by aprotinin
implicates the full uPA/plasmin system in the processes of metastatic
spread. Continuous inhibition of plasmin by aprotinin in mammalian
systems in vivo, however, is difficult to achieve. This could be due to the
short half-life of Kunitz domain inhibitors in mammalian plasma,
including a 150-minute half-life time for aprotinin [42,43], compared
with antibody-based inhibitors, which can persist for days [44]. Fur-
thermore, in some model systems, aprotinin treatment actually in-
creased levels of experimental metastasis [45], indicating that the role
of plasmin in the multistep metastatic cascade can be quite complex.
Inhibition of plasmin activity may also facilitate metastasis by sustain-
ing tumor-cell thrombi, potentially allowing for enhanced tumor cell
survival in circulation and arrest at secondary sites [46,47]. These com-
plex and seemingly contrasting effects of plasmin inhibition on tumor
progression highlight the benefit of targeting the initial step in the
tumor-initiated pro-uPA/uPA/plasminogen/plasmin cascade, that is,
pro-uPA activation. Despite this complexity, the pronounced inhibitory
effect of anti-uPAmAb-112 in reducing levels of spontaneous metastasis
in both the murine and avian models suggests that specifically targeting
pro-uPA activation at the early stages of tumor progression can provide
an overall antimetastatic outcome. Our study, however, does not rule
out a role for the uPA/plasmin cascade in the later events of cancer
Figure 6. Immunohistochemical analysis of matrix collagen and fibronectin in PC-hi/diss primary CAM tumors. Consecutive tissue sec-
tions of frozen normal CAM and PC-hi/diss tumors, harvested from control embryos or embryos treated with aprotinin, were immunos-
tained with antihuman CD44 mAb-29-7 to discriminate PC-hi/diss cells (dark brown, top panels) and mAb-B3/D6 to highlight avian
fibronectin (middle panels). Sections from formalin-fixed paraffin-embedded tumors and normal CAM were stained with Masson trichrome
to highlight collagen fibrils (bottom panels). Images were captured at an original magnification of ×200. Scale bar, 50 μm.
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dissemination such as vascular extravasation and tissue remodeling at
secondary sites.
Consistent with the histologic appearance of the murine xenograft
tumors, a dramatic reduction in formation of the invasive front was
observed in PC-hi/diss primary CAM tumors treated with mAb-112
or aprotinin. This phenomenon was quantitatively evaluated in our
newly developed intramesodermal tumor model, in which microtu-
mors are formed directly in the mesoderm layer of the CAM, facil-
itating early invasion of tumor cells into the surrounding stroma and
allowing for direct treatment and imaging of developing tumors and
escaping cells. By treating the microtumors at early time points, we
demonstrated that the initial PC-hi/diss cell escape was significantly
inhibited by mAb-112 and aprotinin. Importantly, late treatments
with aprotinin did not substantially inhibit invasion of escaping
PC-hi/diss cells into the surrounding stroma. Together, these results
indicate that uPA-generated plasmin is functionally important very
early during tumor escape, possibly at the time when cancer cells ini-
tially break away from the bulk tumor mass. Interestingly, in the
intramesodermal microtumor model, the MMP inhibitor GM6001
was ineffective in blocking the escape of PC-hi/diss carcinoma cells,
in contrast to the significant inhibition by GM6001 of microtumor
escape and invasion of mesenchymal HT-1080 fibrosarcoma cells
(E.I.D., unpublished observations). These findings suggest that uPA/
plasmin–mediated invasion of carcinoma cells may not involve the
activation of MMPs by plasmin and indicate that initial escape and
invasion in this specific model system is mainly mediated by MMP-
independent, uPA/plasmin–governed mechanisms. However, critical
roles of MMPs, such as MMP-1 and MMP-14, were demonstrated
for carcinoma cell dissemination in other model systems, especially
during late events of the metastatic cascade such as osteolytic metas-
tasis of prostate and breast carcinoma cells to the bone [48,49].
The uPA-generated plasmin has broad substrate specificity, and
multiple plasmin substrates may be involved in facilitating early tumor
cell escape, invasion, and dissemination. We speculated that some of
the plasmin ECM substrates may accumulate within and at the stromal
border of developing PC-hi/diss tumors and that plasmin-mediated
cleavage of such substrates might stimulate migration or facilitate inva-
sion and escape of primary tumor cells. Among natural plasmin targets,
Figure 7. uPA activation promotes invasion of three-dimensional fibrillar collagen matrices supplemented with the plasmin substrates
fibronectin and fibrin. (A) Collagen droplets containing PC-hi/diss cells were incorporated into three-dimensional gels containing collagen I
only, a mixture of collagen I and thrombin-clotted fibrin, or a mixture of collagen I and fibronectin, prepared as described in the Materials
and Methods section. All outer gels were supplemented with EGF to induce chemotactic invasion from inner cell–containing collagen
droplets. Gels were overlaid with AIM-V medium supplemented with control IgG or mAb-112. Medium was replaced every 3 to 4 days.
After 10 days of incubation, digital images were captured at an original magnification of ×100. (B) An invasion index was calculated from
individual images by multiplying the individual lengths of invasion by the number of tumor cells invaded beyond the original boundaries
of collagen droplets. At least six images at an original magnification of ×100 were analyzed per variable per experiment. Data are pre-
sented as percent invasion in control (100%) and are the pooled means ± SEM from two to three experiments. *P < .05, one-tailed
Student’s t test.
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fibrin is often considered to be the most physiologically important
plasmin substrate. However, extensive fibrin deposition was not ob-
served in the PC-hi/diss tumors and was not enhanced by aprotinin
treatment, consistent with previous reports demonstrating the lack of
immunohistochemically detectable changes in fibrin deposition within
tumors developing in plasminogen knockout versus control mice, despite
fibrin(ogen) being a critical substrate promoting plasmin-dependent
tumor growth and progression [50].
Figure 8. Cleavage of fibronectin by uPA-generated plasmin as a potential mechanism of enhanced invasion and escape of PC-hi/diss
cells from primary tumors. (A) Cleavage of fibronectin by active plasmin generated by PC-hi/diss uPA. Fibronectin (FN) was incubated in
the presence or absence of PC-hi/diss CM, plasminogen, and aprotinin for 18 hours at 37°C. Samples were boiled in SDS buffer and
separated by SDS-PAGE under nonreducing conditions. Gels were stained with Coomassie blue dye. The position of intact fibronectin
(lanes 2, 4, and 5) is indicated on the right. Fibronectin cleavage products were produced in the presence of PC-hi/diss CM and plas-
minogen (lane 3) but not in the presence of aprotinin (lane 4) or plasminogen alone (lane 5), suggesting uPA-generated plasmin activity.
Asterisk points to a major protein component of PC-hi/diss CM, which was resistant to fibronectin-cleaving activity of the generated
serine proteases (lane 3), further indicating the specificity of fibronectin cleavage by the uPA-generated plasmin. The positions of the
molecular weight markers (kDa) are indicated on the left. (B) Haptotactic migration of PC-hi/diss cells toward plasmin-cleaved fibronec-
tin. The undersides of 8-μm pore Transwells were coated with fibronectin and incubated with plasmin in the presence or absence of
aprotinin. After incubation, Transwells were washed and placed in the wells filled with SF-DMEM. PC-hi/diss cells were placed into the
inserts in SF-DMEM and the cells that had migrated into the outer chambers were counted at 18 to 24 hours (bar graph). Data are
presented as percent migration toward nontreated fibronectin (100%) and are means ± SEM calculated from three independent experi-
ments, each performed in duplicate. **P < .01, two-tailed Student’s t test. Fibronectin cleavage by plasmin and inhibition of this cleav-
age by aprotinin were confirmed in parallel reactions by presence and absence of fibronectin cleavage products in Coomassie-stained
gels (bottom). The positions of the molecular weight markers (kDa) are indicated on the right. (C) CellTracker Green–labeled PC-hi/diss
cells were injected into the CAM mesoderm of day 9 embryos. The microtumors were topically treated with anti–α5 integrin antibody on
day 2 after cell injections. At day 6, the embryos were injected with rhodamine-conjugated lectin, and portions of the CAM containing
microtumors were imaged by fluorescence microscopy. Dashed lines outline microtumor borders and highlight trails of escaping green
fluorescent tumor cells in images captured at an original magnification of ×100. Scale bar, 50 μm. Bar graph, The invasion index for each
variable was calculated as described in the Materials and Methods section from a total of 22 to 24 individual microtumors developed in
five embryos. Data are presented as means ± SEM of the percent of invasion in the control-treated embryos (100%). ***P< .0001, two-
tailed Student’s t test.
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Plasmin-mediated protein modifications have also been implicated
during adipocyte differentiation, when plasmin exerts its effects by
cleaving a nonfibrin substrate, namely fibronectin [51]. Limited cleav-
age of fibronectin by uPA and plasmin has been previously shown in a
model system using avian fibroblasts [17]. Furthermore, fibronectin
itself and fibronectin-integrin interactions have long been linked to
tumor development and metastasis [19,52–54]. A pronounced accu-
mulation of fibronectin within and around the PC-hi/diss tumors was
observed in vivo in the avian xenograft tumor model, especially in
aprotinin-treated tumors. We suggested that plasmin-mediated fibro-
nectin remodeling, mediated by tumor cell uPA, might mechanistically
contribute to PC-hi/diss initial escape and subsequent metastasis. To
validate this notion, we first verified that fibronectin fragments are gener-
ated after treatment with the mixture of plasminogen and uPA-containing
tumor cell CM as a source of plasminogen activator. Supporting a role
for plasmin-modified fibronectin in PC-hi/diss migration, the limited
proteolysis of fibronectin by plasmin substantially enhanced its capac-
ity to induce cell migration in vitro. Accumulation of fibronectin in
aprotinin-treated tumors further validated that proteolytic cleavage of
matrix fibronectin by serine proteases, including plasmin, occurs in vivo
in the tumor-associated stroma. In addition to widespread proteolytic
remodeling and pathway clearing of the tumor tissue ECM, it is likely
that the plasmin-cleaved fibronectin, through interactions with its cell
surface receptor, can facilitate tumor cell escape and invasion in vivo, as
evidenced by the inhibitory effects of blocking α5β1 integrin functions
on escape of PC-hi/diss cells in the intramesodermal microtumor
model. Altogether, our findings point to pro-uPA activation as a critical
process during early stages of cancer cell dissemination and suggest that
fibronectin may be a critical target of the uPA/plasmin proteolytic
cascade involved in the initial invasive escape of carcinoma cells.
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Figure W1. Levels of uPAR at the cell surface of PC-lo/diss and PC-
hi/diss cells. Cell surface levels of uPAR on PC-lo/diss (gray bars)
and PC-hi/diss (black bars) monolayers were determined using
whole-cell ELISA PC-lo/diss and PC-hi/diss cells were seeded at
equal density into 96-well plates precoated with 10 μg/ml type I
collagen in serum-free AIM-V medium (Gibco, Grand Island, NY)
or AIM-V medium supplemented with 0.1% chicken serum. After
24 hours, the cells were washed, fixed in 2% paraformaldehyde,
and blocked with 1% bovine serum albumin in PBS–0.05% Tween
20. Primary mAb 3936 against uPAR (American Diagnostica Inc.,
Stamford, CT) was added at 2 μg/ml in blocking solution for 1 hour
at room temperature, followed by incubation with anti-mouse HRP
(Bio-Rad) at 0.5 μg/ml for 1 hour. After washing, ABTS substrate
was added, and the optical density was determined at 405 nm.
The background readings from control IgG wells were subtracted
from the data. Fold differences in uPAR levels were calculated in
comparison to PC-lo/diss cells incubated without serum (100%).
Data are presented as means ± SEM from triplicate wells.
Figure W2. Immunohistochemical analysis of laminin and fibrin
within primary CAM tumors. Frozen tissue sections from PC-hi/
diss tumors, treated with aprotinin or buffer (vehicle control), were
immunostained with mAb “31 or 31-2” recognizing avian laminin
(top). Positive laminin immunostaining (brown) was associated
with medium-to-large blood vessels in both control and aprotinin-
treated tumors. Formalin-fixed paraffin-embedded sections were
stained with anti-fibrin antibody to visualize fibrin clots, which were
rare in both control and aprotinin-treated tumors and were only
observed intravascularly (bottom). Images were captured at an
original magnification of ×200. Scale bar, 25 μm.
Figure W4. (A) PC-hi/diss cells express functional α5β1 integrin, mediating adhesion to fibronectin. Multiwell plates were coated for
1.5 hours with 10 μg/ml fibronectin, which was left intact or treated with 40 nM plasmin overnight at 37°C. After plate washing and
blocking with 1% bovine serum albumin, PC-hi/diss cells were allowed to adhere for 45 minutes in the presence of function-blocking
antibodies against the β1 or α5 integrin subunits. Nonadherent cells were washed out, and adherent cells were fixed and stained with
crystal violet. Cell-incorporated dye was extracted, and absorption, proportional to the cell number, was measured at 560 nm. Data are
presented as means ± SEM of absorbance from triplicate wells. (B) Cell surface expression of the α5 and β1 integrin subunits in PC-hi/diss
cells was determined by FACS analysis in comparison to control IgG. The cells were incubated for 1 hour with 3 μg/ml primary antibodies at
4°C, followed by incubation with fluorescein isothiocyanate–conjugated secondary anti-mouse antibodies (Sigma).
Figure W3. Accumulation of fibronectin in aprotinin-treated PC-hi/
diss CAM tumors. Normal CAM was harvested from the embryos
on day 16 of incubation. PC-hi/diss primary tumors, treated with
aprotinin or buffer control, were harvested 6 days after cell graft-
ing on the CAM. Harvested tissues were washed and lysed. Lysate
samples containing 20 μg of protein were separated by SDS-PAGE
under nonreducing conditions, transferred to a membrane sup-
port, and probed with mAb–B3/D6 to detect avian fibronectin.
The positions of molecular weight markers (kDa) are indicated
on the left.
